463 related articles for article (PubMed ID: 9738557)
21. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors for survival after isolated limb perfusion for malignant melanoma.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2003 Dec; 29(10):916-21. PubMed ID: 14624788
[TBL] [Abstract][Full Text] [Related]
23. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma.
Zogakis TG; Bartlett DL; Libutti SK; Liewehr DJ; Steinberg SM; Fraker DL; Alexander HR
Ann Surg Oncol; 2001 Dec; 8(10):771-8. PubMed ID: 11776490
[TBL] [Abstract][Full Text] [Related]
24. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.
Pace M; Gattai R; Mascitelli EM; Millanta L
J Surg Oncol; 2011 Dec; 104(7):718-23. PubMed ID: 21721008
[TBL] [Abstract][Full Text] [Related]
25. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs.
Thompson JF; Gianoutsos MP
World J Surg; 1992; 16(2):227-33. PubMed ID: 1561803
[TBL] [Abstract][Full Text] [Related]
26. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
[TBL] [Abstract][Full Text] [Related]
27. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
28. Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007-2018.
Tulokas SKA; Kohtamäki LM; Mäkelä SP; Juteau S; Albäck A; Vikatmaa PJ; Mattila KE; Skyttä TK; Koivunen JP; Tyynelä-Korhonen K; Hernberg MM
Melanoma Res; 2021 Oct; 31(5):456-463. PubMed ID: 34132224
[TBL] [Abstract][Full Text] [Related]
29. TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases: a pilot trial.
Rossi CR; Russano F; Mocellin S; Chiarion-Sileni V; Foletto M; Pilati P; Campana LG; Zanon A; Picchi GF; Lise M; Nitti D
Ann Surg Oncol; 2008 Apr; 15(4):1218-23. PubMed ID: 18247095
[TBL] [Abstract][Full Text] [Related]
30. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
[TBL] [Abstract][Full Text] [Related]
31. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma.
Papadia F; Basso V; Patuzzo R; Maurichi A; Di Florio A; Zardi L; Ventura E; González-Iglesias R; Lovato V; Giovannoni L; Tasciotti A; Neri D; Santinami M; Menssen HD; De Cian F
J Surg Oncol; 2013 Feb; 107(2):173-9. PubMed ID: 22674435
[TBL] [Abstract][Full Text] [Related]
32. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
[TBL] [Abstract][Full Text] [Related]
33. Long-term results of a double perfusion schedule using high dose hyperthermia and melphalan sequentially in extensive melanoma of the lower limb.
Noorda EM; Vrouenraets BC; Nieweg OE; Klaase JM; van der Zee J; Kroon BB
Melanoma Res; 2003 Aug; 13(4):395-9. PubMed ID: 12883366
[TBL] [Abstract][Full Text] [Related]
34. The Effect of Temperature and Perfusion Time on Response, Toxicity, and Survival in Patients with In-transit Melanoma Metastases Treated with Isolated Limb Perfusion.
Katsarelias D; Rådbo E; Ben-Shabat I; Mattsson J; Olofsson Bagge R
Ann Surg Oncol; 2018 Jul; 25(7):1836-1842. PubMed ID: 29766389
[TBL] [Abstract][Full Text] [Related]
35. Myoglobin does not predict local toxicity in isolated limb perfusion.
Nyström Wendt A; Mattsson J; Olofsson Bagge R
Int J Hyperthermia; 2017 Sep; 33(6):679-683. PubMed ID: 28540796
[TBL] [Abstract][Full Text] [Related]
36. Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients.
Madu MF; Deken MM; van der Hage JA; Jóźwiak K; Wouters MWJM; van Akkooi ACJ
Ann Surg Oncol; 2017 Jul; 24(7):1997-2005. PubMed ID: 28188500
[TBL] [Abstract][Full Text] [Related]
37. Melphalan in regional chemotherapy for locally recurrent metastatic melanoma.
Defty CL; Marsden JR
Curr Top Med Chem; 2012; 12(1):53-60. PubMed ID: 22196271
[TBL] [Abstract][Full Text] [Related]
38. A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb.
Lingam MK; Byrne DS; Aitchison T; MacKie RM; McKay AJ
Eur J Cancer; 1996 Sep; 32A(10):1668-73. PubMed ID: 8983272
[TBL] [Abstract][Full Text] [Related]
39. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma.
Vrouenraets BC; Hart GA; Eggermont AM; Klaase JM; van Geel BN; Nieweg OE; Kroon BB
J Am Coll Surg; 1999 May; 188(5):522-30. PubMed ID: 10235581
[TBL] [Abstract][Full Text] [Related]
40. Australian Multicenter Study of Isolated Limb Infusion for Melanoma.
Kroon HM; Coventry BJ; Giles MH; Henderson MA; Speakman D; Wall M; Barbour A; Serpell J; Paddle P; Coventry AG; Sullivan T; Smithers BM; Thompson JF
Ann Surg Oncol; 2016 Apr; 23(4):1096-103. PubMed ID: 26581203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
